Ewopharma and Dr. Falk Pharma renew their long-standing partnership - a commitment built to last
Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more…
Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more…
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recom…
Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CSton…
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and…
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to ann…
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CS…
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to ann…
Ewopharma, a pharmaceutical marketing company and Eisai Europe Ltd., a leading global research and development-based pha…
Tuberculoza (TBC) este principala cauză de deces provocat de o boală infecțioasă, la nivel global.[1] Otsuka Pharmaceuti…
Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewo…